Top 5 Undervalued Stocks To Buy For 2019


Gilead Sciences (GILD) is a large capitalization pharmaceutical and biotechnology company best known for its HIV and HCV (hepatitis C) therapies.

After Gilead showed it could generate large amounts of revenue from new, highly effective cures for HCV, its stock price rose to a peak of $123.57 per share in June 2015. That was quite a climb upward from $37.16 per share at the beginning of 2013, but since then the stock price, although volatile, has drifted mainly downward.

Harvoni pill. Source: Gilead.com

Many analysts and financial journalists, including this author, believe that Gilead is undervalued. Yet despite that, good news has not lifted the price of the stock for long in 2016 or 2017. After briefly reviewing the causes of the low stock valuation, I will cover three future catalysts that should boost the stock price. But my current thesis is that the stock price is governed by psychology, not fundamentals. I do not pretend to know for certain what change in investor psychology might bring Gilead up to fair valuation.

Top 5 Undervalued Stocks To Buy For 2019: Information Services Group Inc.(III)


Advisors’ Opinion:

  • [By Joseph Griffin]

    RMR Group (NASDAQ: RMR) and Information Services Group (NASDAQ:III) are both finance companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings.

  • [By Logan Wallace]

    CGI Group (NYSE: GIB) and Information Services Group (NASDAQ:III) are both computer and technology companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

  • [By Joseph Griffin]

    3i Group (LON:III) had its price target upped by Societe Generale from GBX 1,020 ($13.58) to GBX 1,130 ($15.04) in a research note released on Thursday. The brokerage currently has a buy rating on the stock.

  • [By Joseph Griffin]

    Get a free copy of the Zacks research report on Information Services Group, Inc. Common Stock (III)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top 5 Undervalued Stocks To Buy For 2019: Smart(SFS)


Advisors’ Opinion:

  • [By Joseph Griffin]

    ValuEngine lowered shares of Smart & Final Stores (NYSE:SFS) from a sell rating to a strong sell rating in a research report released on Wednesday.

  • [By Lisa Levin]

     

    Losers
    Heat Biologics, Inc. (NASDAQ: HTBX) shares tumbled 48.59 percent to close at $1.275 on Thursday after the company priced its $18,000,000 public offering.
    InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) fell 38.77 percent to close at $8.26 on Thursday.
    Check-Cap Ltd. (NASDAQ: CHEK) shares tumbled 27.43 percent to close at $8.81.
    Achaogen, Inc. (NASDAQ: AKAO) dropped 24.76 percent to close at $11.06 in reaction to a disappointing update from an FDA AdCom panel. The FDA panel voted favorably for the company's Plazcomicin for treatment of adults with complicated urinary tract infections, but also voted against the therapy to be used as a treatment for bloodstream infections.
    Anika Therapeutics, Inc. (NASDAQ: ANIK) shares declined 24.68 percent to close at $34.80 after the company posted downbeat quarterly results.
    LSC Communications, Inc. (NASDAQ: LKSD) shares fell 24.22 percent to close at $12.64 following wider-than-expected Q1 loss.
    Cardinal Health, Inc. (NYSE: CAH) fell 21.42 percent to close at $50.80 following downbeat quarterly profit.
    Horizon Global Corporation (NYSE: HZN) dropped 20.42 percent to close at $6.00 following downbeat quarterly earnings.
    Hornbeck Offshore Services, Inc. (NYSE: HOS) slipped 20.11 percent to close at $2.90 following wider-than-expected Q1 loss.
    Esperion Therapeutics, Inc. (NASDAQ: ESPR) fell 19.28 percent to close at $36.93. Esperion Therapeutics stock lost roughly a third of its value Wednesday after the company reported mixed Phase III results for its leading drug candidate, bempedoic acid. JP Morgan downgraded Esperion Therapeutics from Neutral to Underweight.
    Laredo Petroleum, Inc. (NYSE: LPI) declined 17.77 percent to close at $8.98 after the company reported weaker-than-expected Q1 earnings.
    The Habit Restaurants, Inc. (NASDAQ: HABT) dipped 16.1 percent to close at $8.60 after the company reported downbeat quarterly results.
    Arcadia Biosciences, Inc. (N

  • [By Brian Stoffel]

    But over the past five years, the industry has been turned upside down by changes in business models, a focus on delivery, and mass consolidation. While the dust is far from settled, here are 10 of the largest publicly traded grocers you can buy stock in.

    Company Market Cap Stores Regions Chains
    Amazon (NASDAQ:AMZN) $780 billion 500 USA Whole Foods
    Walmart (NYSE:WMT) $250 billion 11,700 Worldwide Walmart
    Costco (NASDAQ:COST) $86 billion 750 USA Costco
    Kroger (NYSE:KR) $21 billion 2,800 USA Kroger, Roundy’s, Ralph’s, Food 4 Less
    Sprouts (NASDAQ: SFM) $3 billion 300 Western and Southern U.S. Sprouts Farmer’s Market
    Weis Market (NYSE: WMK) $1.3 billion 200 Mid-Atlantic U.S. Weis Market
    SUPERVALU(NYSE: SVU) $630 million 100 Midwestern U.S. Cub Foods, Shopper’s Food, Hornbacher
    Ingles Market(NASDAQ: IMKTA) $580 million 200 Southeastern U.S. Ingles Market, Sav-Mor
    Smart & Final(NYSE: SFS) $360 million 350 Western U.S. Smart & Final, Cash & Carry
    Natural Grocers (NYSE: NGVC) $230 million 150 Western U.S. Natural Grocers


    Data source: Yahoo! Finance, company websites.

  • [By Shane Hupp]

    Smart & Final (NYSE: SFS) and Kroger (NYSE:KR) are both consumer staples companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, earnings, analyst recommendations, valuation and risk.

Top 5 Undervalued Stocks To Buy For 2019: International Speedway Corporation(ISCA)

Advisors’ Opinion:

  • [By Logan Wallace]

    Get a free copy of the Zacks research report on International Speedway Corp Class A (ISCA)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Logan Wallace]

    Get a free copy of the Zacks research report on International Speedway Corp Class A (ISCA)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Motley Fool Staff]

    International Speedway Corporation (NASDAQ: ISCA)Q2 2018 Earnings Conference callJul. 05, 2018, 1:00 pm ET


    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator

Top 5 Undervalued Stocks To Buy For 2019: Coca-Cola Bottling Co. Consolidated(COKE)

Advisors’ Opinion:

  • [By Logan Wallace]

    Coca-Cola Bottling Co. Consolidated (NASDAQ: COKE) and Coca Cola Femsa (NYSE:KOF) are both consumer staples companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, dividends, profitability, institutional ownership, analyst recommendations, risk and valuation.

  • [By Ethan Ryder]

    Coca-Cola Bottling Co. Consolidated (NASDAQ:COKE) released its quarterly earnings data on Tuesday. The company reported ($0.85) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.88 by ($1.73), reports. Coca-Cola Bottling Co. Consolidated had a return on equity of 11.63% and a net margin of 2.23%.

Top 5 Undervalued Stocks To Buy For 2019: Sarepta Therapeutics, Inc.(SRPT)

Advisors’ Opinion:

  • [By Dan Caplinger]

    That only makes it more important to be selective about the stocks you choose to own. Even under more difficult market conditions, some stocks have continued to push sharply higher. HollyFrontier (NYSE:HFC), Boot Barn Holdings (NYSE:BOOT), and Sarepta Therapeutics (NASDAQ:SRPT) have each tripled since this time last year, and bullish shareholders think that there could be further gains in store for the three companies if some key things keep going right.

  • [By Keith Speights]

    Three gene therapy stocks aren’t just hotin 2018 — they’re red-hot. Shares ofSarepta Therapeutics (NASDAQ:SRPT), Solid Biosciences (NASDAQ:SLDB), and uniQure(NASDAQ:QURE)have nearly doubled or generated even greater gains so far this year. But is it too late for investors to buy these gene therapy stocks? Here’s what you need to know.

  • [By Keith Speights]

    But some stocks don’t take nearly that long to double. Three stocks in particularhave doubled investors’ money — and more — in just the last 12 months. Here’s why Nektar Therapeutics (NASDAQ:NKTR), CRISPR Therapeutics (NASDAQ:CRSP), and Sarepta Therapeutics (NASDAQ:SRPT) became such huge winners — and whether or not their impressive momentum can continue.

Leave a Reply

Your email address will not be published.